GRAFT POLYMER UK LS -001 (F:J4I) — Market Cap & Net Worth
Market Cap & Net Worth: GRAFT POLYMER UK LS -001 (J4I)
GRAFT POLYMER UK LS -001 (F:J4I) has a market capitalization of $12.00 Million (€10.26 Million) as of May 3, 2026. Listed on the F stock exchange, this Germany-based company holds position #26417 globally and #2282 in its home market, demonstrating a -28.57% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying GRAFT POLYMER UK LS -001's stock price €0.00 by its total outstanding shares 6806403493 (6.81 Billion).
GRAFT POLYMER UK LS -001 Market Cap History: 2022 to 2026
GRAFT POLYMER UK LS -001's market capitalization history from 2022 to 2026. Data shows change from $1.12 Billion to $19.89 Million (-65.96% CAGR).
GRAFT POLYMER UK LS -001 Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how GRAFT POLYMER UK LS -001's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of J4I by Market Capitalization
Companies near GRAFT POLYMER UK LS -001 in the global market cap rankings as of May 3, 2026.
Key companies related to GRAFT POLYMER UK LS -001 by market ranking:
- GE Vernova LLC (NYSE:GEV): Ranked #82 globally with a market cap of $229.98 Billion USD.
- Siemens Aktiengesellschaft (XETRA:SIE): Ranked #113 globally with a market cap of $184.02 Billion USD ( €157.40 Billion EUR).
- SIEMENS AG SP. ADR 1/ 1/2 (F:SIEB): Ranked #119 globally with a market cap of $177.31 Billion USD ( €151.67 Billion EUR).
- Schneider Electric S.E. (PA:SU): Ranked #156 globally with a market cap of $143.23 Billion USD ( €122.51 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #82 | GE Vernova LLC | NYSE:GEV | $229.98 Billion | $1062.95 |
| #113 | Siemens Aktiengesellschaft | XETRA:SIE | $184.02 Billion | €252.55 |
| #119 | SIEMENS AG SP. ADR 1/ 1/2 | F:SIEB | $177.31 Billion | €119.00 |
| #156 | Schneider Electric S.E. | PA:SU | $143.23 Billion | €268.60 |
GRAFT POLYMER UK LS -001 Historical Marketcap From 2022 to 2026
Between 2022 and today, GRAFT POLYMER UK LS -001's market cap moved from $1.12 Billion to $ 19.89 Million, with a yearly change of -65.96%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €19.89 Million | +150.00% |
| 2025 | €7.96 Million | +100.00% |
| 2024 | €3.98 Million | 0.00% |
| 2023 | €3.98 Million | -99.65% |
| 2022 | €1.12 Billion | -- |
End of Day Market Cap According to Different Sources
On May 3rd, 2026 the market cap of GRAFT POLYMER UK LS -001 was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $12.00 Million USD |
| MoneyControl | $12.00 Million USD |
| MarketWatch | $12.00 Million USD |
| marketcap.company | $12.00 Million USD |
| Reuters | $12.00 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About GRAFT POLYMER UK LS -001
Solvonis Therapeutics plc, a clinical-stage biopharmaceutical company, develops novel medicines for addiction and mental health disorders. The company develops SVN-001, an NMDA receptor antagonist that is in Phase III clinical trial for the treatment of severe alcohol use disorder; and SVN-002, which has completed Phase I clinical trial to treat moderate to severe alcohol use disorder. Its pre-cl… Read more